Blood Pressure After Endovascular Stroke Therapy-II

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

December 15, 2022

Conditions
Acute StrokeEndovascular Thrombectomy
Interventions
DRUG

Nicardipine

In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.

DRUG

Labetalol

If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.

DRUG

Hydralazine

If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.

Trial Locations (3)

37203

Vanderbilt University Medical Center, Nashville

45221

University of Cincinnati, Cincinnati

06103

Hartford Healthcare, Hartford

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Vanderbilt University Medical Center

OTHER

lead

University of Cincinnati

OTHER

NCT04116112 - Blood Pressure After Endovascular Stroke Therapy-II | Biotech Hunter | Biotech Hunter